Lundbeck to highlight mechanistic insights on bexicaserin's dual mode of action at the European Epilepsy Congress

Preclinical data suggest bexicaserin has a dual mode of action—reducing excitatory neuronal activity while increasing inhibitory activity—indicating broader antiseizure potential. The findings span focal, generalized motor, and absence seizure models across different conditions, though they are limited to preclinical evidence.